Peptide Drug Conjugation Service
Peptide drug Conjugation (PDC) has emerged as a promising class of targeted therapeutics in the field of rare disease drug development. Our company offers a one-stop service for PDC development, encompassing design, and optimization to preclinical and clinical studies, dedicated to providing service for rare disease peptide therapies.
Introduction to Peptide Drug Conjugation
Peptide-drug conjugations (PDC), which combine the advantages of peptides, have emerged as a new generation of targeted therapies for rare diseases, following Antibody-drug conjugation (ADC). PDC has the advantages of smaller molecular weight, less likelihood of causing autoimmune reactions, and ease of synthesis, making them a promising alternative to small molecule drugs, monoclonal antibodies, and ADC. PDC consists of homing peptides, cytotoxic payloads, and junctions that work together to deliver chemotherapeutic agents.
PDC for Rare Diseases
Peptides have versatile roles in various biological processes and offer targeted delivery capabilities. PDC can be used to treat a variety of rare diseases, not only in endocrine diseases but also in oncology. PDC is the next generation of targeted therapeutics after ADC, and their core advantages are enhanced cell permeability and improved drug selectivity. Several PDC drugs have been approved for marketing in the world.
|Types of Rare Diseases Targeted
|Somatostatin Receptor 2 (SSTR2)
|Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
|Low-Density Lipoprotein Receptor (LDLR)
|Glioblastoma Multiforme (GBM)
PDC offers a new paradigm in rare disease treatment by combining the benefits of peptide-based drugs. Unlike traditional anticancer therapies, PDC utilizes smaller molecular compositions, enhancing biochemical stability, cell membrane penetration, and overall efficacy. Our company offers customized coupling services for peptide carriers, linkers, and payload drugs.
- Peptide Carrier
We offer the common peptide carrier, including cell-penetrating peptides and cell-targeting peptides.
Similarly, when it comes to rare diseases, the choice of linker for peptide conjugation is also target-dependent. Factors such as the drug molecule used, the site of conjugation, the number of attachment sites available, and the desired cleavability and polarity of the linker all influence the selection process. We offer a variety of linkers for peptide conjugation, including cleavage linkers and non-cleavage linkers.
- Cleavage linkers: Hydrazine (pH-sensitive), Glycine-Phenylalanine-Leucine-Glycine (enzyme-sensitive), Disulfide bond (reduction-sensitive).
- Non-cleavage linkers: Carbon chains, Amido bonds, and Ether bonds.
- Payload Drugs
Any drugs you are interested in include but are not limited to: Doxorubicin (DOX), Paclitaxel (PTX), and Camptothecin (CPT).
Through ongoing research and development, peptide conjugation continues to pave the way for the future of precision medicine and personalized therapies for rare diseases. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
- Fu, Chen, et al. "Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?." Acta Pharmaceutica Sinica B 13.2 (2023): 498-516.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.